1. Topical therapies- keratolytic agents such as salicylic acid; cytotoxic agents like 5-Fluorouracil, bleomycin and podophyllin; immunomodulators like imiquimod and caustics such as trichloroacetic acid.

2. Destructive therapies- electrofulguration, cryotherapy, laser ablation, excision, hyperthermia and photodynamic therapy.

3. Immunotherapies- vaccines such as BCG, MMR, Mycobacterium w; antigens such as candid antigen, PPD, vitamin D-3, IFN-alpha and contact sensitizers.

        Topical therapy generally requires multiple sessions which results in poor patient compliance and has a higher risk of recurrence. Destructive modalities often require expensive equipment, cause scarring and dyspigmentation.

         Immunotherapy has evoloved as a potential treatment modality for treatment of warts which acts by activating the patient’s immune system thus enhancing recognition and eradication of the virus. Vitamin D-3 is a recent introduction as immunotherapeutic agent which regulates epidermal proliferation and cytokine production.

         Bleomycin, a cytotoxic agent has been U.S FDA approved for the treatment of various malignancies. When administered into the skin, it leads to apoptosis of keratinocytes by causing DNA breaks, endothelial cell sclerosis, and inhibition of collagen formation. The therapeutic efficacy of bleomycin in warts have been assessed by using various concentrations, doses and different methods of administration.

          This study aims at comparing the therapeutic efficacy of intralesional bleomycin and intralesional vitamin D-3 in verruca vulgaris.